Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.
暂无分享,去创建一个
Sarat Chandarlapaty | Brian M Zeglis | Dara S Ross | Gary A Ulaner | David M Hyman | Vaios Hatzoglou | S. Chandarlapaty | Jason S. Lewis | V. Hatzoglou | D. Ross | D. Hyman | J. Carrasquillo | K. Jhaveri | B. Zeglis | C. Riedl | G. Ulaner | Jason S Lewis | Christopher C Riedl | Jorge A Carrasquillo | Randy Yeh | Komal Jhaveri | Serge K Lyashchenko | R. Yeh | S. Lyashchenko | Jason S. Lewis | Brian M. Zeglis
[1] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Y. Bang,et al. HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.
[3] M. Morris,et al. Long–Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer , 2017, The Journal of Nuclear Medicine.
[4] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[5] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[6] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[7] R. Bose,et al. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. , 2019, Cancer biotherapy & radiopharmaceuticals.
[8] Jason S. Lewis,et al. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. , 2018, PET clinics.
[9] Gary A Ulaner,et al. First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer , 2017, The Journal of Nuclear Medicine.
[10] R. Pierce,et al. Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts , 2014, Molecular pharmaceutics.
[11] Pieter Wesseling,et al. Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.
[12] Jason S. Lewis,et al. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab , 2020, Theranostics.
[13] A. Bleyer,et al. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. , 2013, JAMA.
[14] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[15] D. Noh,et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. , 2011, Japanese journal of clinical oncology.
[16] Jason S. Lewis,et al. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. , 2017, PET clinics.
[17] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[18] I. Brandslund,et al. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer , 2013, Clinical chemistry and laboratory medicine.
[19] Adrian V. Lee,et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.
[20] Jason S. Lewis,et al. Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.
[21] Lynn C Francesconi,et al. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. , 2013, Nuclear medicine and biology.
[22] Serge K. Lyashchenko,et al. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT , 2016, The Journal of Nuclear Medicine.